High-avidity CD8+ T cells: Optimal soldiers in the war against viruses and tumors

Immunologic Research

Volumn 31, Issue 1, 2005, Pages 13-24

  Alexander Miller, Martha A ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Avidity; CD8+; Regulation; T cells; Tumors; Viral clearance

Indexed keywords

CD8 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN;

ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; CELL SPECIFICITY; EFFECTOR CELL; IMMUNE RESPONSE; MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULAR BIOLOGY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SENSITIVITY ANALYSIS; T LYMPHOCYTE ACTIVATION; VACCINATION; VIRUS CELL INTERACTION; VIRUS INFECTION;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; HUMANS; NEOPLASMS; VIRUS DISEASES;

EID: 11244299387     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1385/IR:31:1:13     Document Type: Review

References (49)

1. Alexander-Miller MA, Leggatt GR, Berzofsky JA: Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc Natl Acad Sci USA 1996;93:4102-4107.
2. Sedlik C, Dadaglio G, Saron MF, Deriaud E, Rojas M, Casal SI, Leclerc C: In vivo induction of a high-avidity, high-frequency cytotoxic T- lymphocyte response is associated with antiviral protective immunity. J Virol 2000;74:5769-5775.
3. Gallimore A, Dumrese T, Hengartner H, Zinkernagel RM, Rammensee HG: Protective immunity does not correlate with the hierarchy of virus-specific cytotoxic T cell responses to naturally processed peptides. J Exp Med 1998;187:1647-1657.
4. Messaoudi I, Guevara Patino JA, Dyall R, LeMaoult J, Nikolich-Zugich J: Direct link between MHC polymorphism, T cell avidity, and diversity in immune defense. Science 2002;298:1797-1800.
5. Dutoit V, Rubio-Godoy V, Dietrich PY, Quiqueres AL, Schnuriger V, Rimoldi D, et al.: Heterogeneous T-cell response to MAGE-A 10(254-262): high-avidity-specific cytolytic T lymphocytes show superior antitumor activity. Cancer Res 2001;61:5850-5856.
6. Yee C, Savage PA, Lee PP, Davis MM, Greenberg PD: Isolation of high-avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J Immunol 1999;162:2227-2234.
7. Snyder JT, Alexander-Miller MA, Berzofsky JA, Belyakov IM: Molecular mechanisms and biological significance of CTL avidity. Curr HIV Res 2003;1: 287-294.
8. Walter S, Herrgen L, Schoor O, Jung G, Wernet D, Buhring HJ, Rammensee HG, Stevanovic S: Cutting edge: predetermined avidity of human CD8 T cells expanded on calibrated MHC/anti-CD28-coated microspheres. J Immunol 2003;171:4974-4978.
9. Cawthon AG, Lu H, Alexander-Miller MA: Peptide requirement for CTL activation reflects the sensitivity to CD3 engagement: correlation with CD8αβ versus CD8αα expression. J Immunol 2001;167:2577-2584.
10. Derby M, Alexander-Miller M, Tse R, Berzofsky J: High-avidity CTL exploit two complementary mechanisms to provide better protection against viral infection than low-avidity CTL. J Immunol 2001;166: 1690-1697.
11. Mealey RH, Zhang B, Leib SR, Littke MH, McGuire TC: Epitope specificity is critical for high and moderate avidity cytotoxic T lymphocytes associated with control of viral load and clinical disease in horses with equine infectious anemia virus. Virology 2003;313:537-552.
12. Zeh HJ, III, Perry-Lalley D, Dudley ME, Rosenberg SA, Yang JC: High-avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J Immunol 1999;162:989-994.
13. Busch DH, Pamer EG: T cell affinity maturation by selective expansion during infection. J Exp Med 1999;189:701-710.
14. al Ramadi BK, Jelonek MT, Boyd LF, Margulies DH, Bothwell AL: Lack of strict correlation of functional sensitization with the apparent affinity of MHC/peptide complexes for the TCR. J Immunol 1995;155:662-673.
15. Echchakir H, Dorothee G, Vergnon I, Menez J, Chouaib S, Mami-Chouaib F: Cytotoxic T lymphocytes directed against a tumor-specific mutated antigen display similar HLA tetramer binding but distinct functional avidity and tissue distribution. Proc Natl Acad Sci USA 2002; 99:9358-9363.
16. Reignat S, Webster GJM, Brown D, Ogg GS, King A, Seneviratne SL, et al.: Escaping high viral load exhaustion: CD8 cells with altered tetramer binding in chronic Hepatitis B virus infection. J Exp Med 2002;195: 1089-1101.
17. + T cells for melanoma immunotherapy in human MHC class I-transgenic mice. J Immunol 2001;167:5824-5831.
18. Lawson TM, Man S, Wang ECY, Williams S, Amos N, Gillespie GM, et al.: Functional differences between influenza A-specific cytotoxic T lymphocyte clones expressing dominant and subdominant TCR. Int Immunol 2001;13:1383-1390.
19. Palermo B, Campanelli R, Mantovani S, Lantelme E, Manganoni AM, Carella G, et al.: Diverse expansion potential and heterogeneous avidity in tumor-associated antigen-specific T lymphocytes from primary melanoma patients. Eur J Immunol 2001;31:412-420.
20. Drake DR, III, Braciale TJ: Cutting edge: lipid raft integrity affects the efficiency of MHC class I tetramer binding and cell surface TCR arrangement on CD8+ T cells. J Immunol 2001;166:7009-7013.
21. Fahmy TM, Bieler JG, Edidin M, Schneck JP: Increased TCR avidity after T cell activation: a mechanism for sensing low-density antigen. Immunity 2001;14:135-143.
22. Cawthon AG, Alexander-Miller MA: Optimal colocalization of TCR and CD8 as a novel mechanism for the control of functional avidity. J Immunol 2002;169: 3492-3498.
23. Zamoyska R, Basson A, Filby A, Legname G, Lovatt M, Seddon B: The influence of the src-family kinases, Lck and Fyn, on T cell differentiation, survival and activation. Immunol Rev 2003;191:107-118.
24. van der Merwe PA, Davis SJ: Molecular interactions mediating T cell antigen recognition. Annu Rev Immunol 2003;21:659-684.
25. Viola A, Schroeder S, Sakakibara Y, Lanzavecchia A: T lymphocyte costimulation mediated by reorganization of membrane microdomains. Science 1999;283:680-682.
26. Wulfing C, Sumen C, Sjaastad MD, Wu LC, Dustin ML, Davis MM: Costimulation and endogenous MHC ligands contribute to T cell recognition. Nat Immunol 2002;3:42-47.
27. Huang J, Lo PF, Zal T, Gascoigne NR, Smith BA, Levin SD, Grey HM: CD28 plays a critical role in the segregation of PKC theta within the immunologic synapse. Proc Natl Acad Sci USA 2002;99:9369-9373.
28. Wetzel SA, McKeithan TW, Parker DC: Live-cell dynamics and the role of costimulation in immunological synapse formation. J Immunol 2002;169:6092-6101.
29. + T cells by exogenous cell-associated antigens. Immunity 2002;17:211-220.
30. + T cells are the initial population elicited following viral infection of the respiratory tract. J Immunol 2003;170:174-181.
31. Gray PM, Parks GD, Alexander-Miller MA: A novel CD8-independent high-avidity cytotoxic T-lymphocyte response directed against an epitope in the phosphoprotein of the paramyxovirus simian virus 5. J Virol 2001;75:10065-10072.
32. + T cells without selection of higher affinity TCR. Nat Immunol 2001;2:711-717.
33. Alexander-Miller MA, Leggatt GR, Sarin A, Berzofsky JA: Role of antigen, CD8, and cytotoxic T lymphocyte (CTL) avidity in high dose antigen induction of apoptosis of effector CTL. J Exp Med 1996;184:485-492.
34. Dyall R, Messaoudi I, Janetzki S, Nikolic-Zugic J: MHC polymorphism can enrich the T cell repertoire of the species by shifts in intrathymic selection. J Immunol 2000;164:1695-1698.
35. Wherry EJ, Puorro KA, Porgador A, Eisenlohr LC: The induction of virus-specific CTL as a function of increasing epitope expression: responses rise steadily until excessively high levels of epitope are attained. J Immunol 1999;163:3735-3745.
36. + T cell memory in response to low, high, and excessive levels of epitope. J Immunol 2002;168:4455-4461.
37. + T cells. J Immunol 2003;170:1822-1829.
38. + T cell responses in vivo and in vitro. Proc Natl Acad Sci USA 1999;96:9781-9786.
39. Oh S, Hodge JW, Ahlers JD, Burke DS, Schlom J, Berzofsky JA: Selective induction of high-avidity CTL by altering the balance of signals from APC. J Immunol 2003;170:2523-2530.
40. Moskophidis D, Lechner F, Pircher H, Zinkernagel RM: Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature 1993;362:758-761.
41. Gallimore A, Glithero A, Godkin A, Tissot AC, Pluckthun A, Elliott T, et al.: Induction and exhaustion of lymphocytic choriomeningitis virus-specific cytotoxic T lymphocytes visualized using soluble tetrameric major histocompatibility complex class I-peptide complexes. J Exp Med 1998;187:1383-1393.
42. + T cells. Eur J Immunol 1993;23:3306-3311.
43. Lechner F, Wong DK, Dunbar PR, Chapman R, Chung RT, Dohrenwend P, et al.: Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 2000;191:1499-1512.
44. + T cells produce antiviral cytokines but are impaired in cytolytic function. J Exp Med 2000;192:63-75.
45. Zajac AJ, Blattman JN, Murali-Krishna K, Sourdive DJ, Suresh M, Altman JD, Ahmed R: Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med 1998;188:2205-2213.
46. Welsh RM: Assessing CD8 T cell number and dysfunction in the presence of antigen. J Exp Med 2001;193: 19F-22.
47. + T cells with a defect in effector function that is reversible on extended interleukin-2 incubation. J Virol 2001;75:3028-3033.
48. Alexander-Miller MA, Derby MA, Sarin A, Henkart PA, Berzofsky JA: Supraoptimal peptide-major histocompatibility complex causes a decrease in bcl-2 levels and allows tumor necrosis factor alpha receptor II- mediated apoptosis of cytotoxic T lymphocytes. J Exp Med 1998;188:1391-1399.
49. Zheng L, Fisher G, Miller RE, Peschon J, Lynch DH, Lenardo MJ: Induction of apoptosis in mature T cells by tumour necrosis factor. Nature 1995;377:348-351.